The University of Chicago Header Logo

Connection

Walter M. Stadler to Cancer Vaccines

This is a "connection" page, showing publications Walter M. Stadler has written about Cancer Vaccines.
Connection Strength

0.270
  1. Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget. 2016 10 18; 7(42):69014-69023.
    View in: PubMed
    Score: 0.125
  2. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8.
    View in: PubMed
    Score: 0.073
  3. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs. 2009 Aug; 27(4):379-86.
    View in: PubMed
    Score: 0.072
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.